Acer Therapeutics to Participate in August and September 2022 Investor Conferences

Rhea-AI Summary

Acer Therapeutics Inc. (Nasdaq: ACER) recently announced that its management will participate in two significant upcoming conferences: the Gilmartin Group Emerging Growth Company Showcase and the H.C. Wainwright 24th Annual Global Investment Conference. The recorded presentation for the Gilmartin conference will be available on August 31, 2022, at 10:30 am ET, while the H.C. Wainwright presentation will go live on September 12, 2022, at 7 am ET. These presentations will focus on Acer's commitment to developing therapies for serious, rare diseases.

NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually present at, and participate in, the upcoming Gilmartin Group Emerging Growth Company Showcase and H.C. Wainwright 24^th Annual Global Investment Conference.

Conference: Gilmartin Group Emerging Growth Company Showcase
Format: Recorded corporate presentation
Date and Time: Recorded presentation available at 10:30 am ET, August 31, 2022
Register: https://gilmartin-emerging-growth-conference.open-exchange.net/registration
Webcast: https://kvgo.com/corporate-services/acer-therapeutics-aug-2022

Conference: H.C. Wainwright 24^th Annual Global Investment Conference
Format: On-demand recorded corporate presentation and one-on-one virtual meetings
Date and Time: On-demand corporate presentation available beginning at 7 am ET, September 12, 2022
Webcast: https://journey.ct.events/view/09133963-6072-4f07-864c-3ed9b50db443

About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four investigational programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, Zika, dengue, Ebola and COVID-19. For more information, visit www.acertx.com.

Corporate and IR Contact
Jim DeNike
Acer Therapeutics Inc.
jdenike@acertx.com
+1-844-902-6100

Nick Colangelo
Gilmartin Group
nick@gilmartinIR.com
+1-332-895-3226

FAQ

When will Acer Therapeutics present at the Gilmartin Group Emerging Growth Company Showcase?

Acer Therapeutics will present at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 10:30 am ET.

What is the date for Acer's presentation at the H.C. Wainwright Annual Global Investment Conference?

Acer's presentation at the H.C. Wainwright 24th Annual Global Investment Conference will be available on September 12, 2022, starting at 7 am ET.

What is the focus of Acer Therapeutics' presentations at the upcoming conferences?

Acer Therapeutics will focus on its commitment to developing therapies for serious, rare, and life-threatening diseases.

Where can I register for Acer's presentations?

You can register for Acer's presentations at the Gilmartin Group conference [here](https://gilmartin-emerging-growth-conference.open-exchange.net/registration) and for the H.C. Wainwright conference [here](https://journey.ct.events/view/09133963-6072-4f07-864c-3ed9b50db443).

What is the ticker symbol for Acer Therapeutics?

The ticker symbol for Acer Therapeutics is ACER.